Insulet — May 6, 2026 release

First Quarter Financial Highlights: • Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency 1 , and exceeded the high end of the Company’s guidance range of 25% - 27% at constant currency rates ◦ Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency ▪ U.S. Omnipod revenue of $515.6 million, increased 28.3% ▪ International Omnipod revenue of $242.9 million, increased 59.4%, or 45.2% in constant currency ◦ Drug Delivery revenue of $3.3 million • Operating income of $122.1 million, or 16.0% of revenue, up 40 basis points over prior year • Adjusted operating income 1 of $133.5 million, or 17.5% of revenue, up 110 basis points over prior year • Net income of $91.1 million, or $1.30 per diluted share, compared to $35.4 million, or $0.50 per diluted share, in the prior year • Adjusted net income 1 of $99.8 million, or $1.42 per diluted share, increased 35.4% and 39.7%, respectively, compared to $73.7 million, or $1.02 per diluted share, in the prior year Recent Strategic Highlights: • Launched Omnipod 5 and Omnipod Discover™ in five countries in the Middle East, bringing Omnipod 5 availability to 19 countries • Presented data on the new Omnipod 5 algorithm update at the Advanced Technologies & Treatments for Diabetes (ATTD) International Conference following a successful limited market release, with broader launch expected in the coming weeks; the latest Omnipod 5 algorithm update delivers improved automation and performance, adding a new 100 mg/dL target glucose for greater personalizatio